Alexion results were encouraging and failed in the pivotal trials
Why did it happened? These were large double blind trials with low p values. Why is that (and that is not only Alexion) that you frequently have great double blind phase II and phase II results followed by a bomb in the pivotal trial? Anybody has any good explanation?